MX2012001527A - Composicion inmunogenica que comprende proteinas antigenicas de s. aureus. - Google Patents

Composicion inmunogenica que comprende proteinas antigenicas de s. aureus.

Info

Publication number
MX2012001527A
MX2012001527A MX2012001527A MX2012001527A MX2012001527A MX 2012001527 A MX2012001527 A MX 2012001527A MX 2012001527 A MX2012001527 A MX 2012001527A MX 2012001527 A MX2012001527 A MX 2012001527A MX 2012001527 A MX2012001527 A MX 2012001527A
Authority
MX
Mexico
Prior art keywords
staphylococcal
immunogenic composition
domain
protein
antigenic
Prior art date
Application number
MX2012001527A
Other languages
English (en)
Inventor
Cindy Castado
Sophie Marie Jeanne Valentine Germain
Melanie Gilbert
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2012001527A publication Critical patent/MX2012001527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente solicitud se refiere a una composición inmunogénica que comprende un fragmento de una proteína lsd estafilocócica, tal como IsdA, lsdB, lsdC o lsdH, que comprende un dominio NEAT. También se dan a conocer proteínas de fusión que comprenden un dominio NEAT de una primera proteína lsd estafilocócica, y un dominio NEAT a partir de una segunda proteína lsd, así como proteínas de fusión que comprenden un dominio NEAT de una proteína lsd estafilocócica involucrada en un sistema de absorción de hierro/hem, y un dominio de enlace de ligando de una proteína de enlace de componente extracelular estafilocócico, por ejemplo, CIfA, CIfB, SdrC, SdrD o SdrE.
MX2012001527A 2009-08-05 2010-08-03 Composicion inmunogenica que comprende proteinas antigenicas de s. aureus. MX2012001527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0913681.3A GB0913681D0 (en) 2009-08-05 2009-08-05 Immunogenic composition
PCT/EP2010/061314 WO2011015591A1 (en) 2009-08-05 2010-08-03 Immunogenic composition comprising antigenic s. aureus proteins

Publications (1)

Publication Number Publication Date
MX2012001527A true MX2012001527A (es) 2012-02-29

Family

ID=41129687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001527A MX2012001527A (es) 2009-08-05 2010-08-03 Composicion inmunogenica que comprende proteinas antigenicas de s. aureus.

Country Status (14)

Country Link
US (1) US20120141523A1 (es)
EP (1) EP2461824A1 (es)
JP (1) JP2013501027A (es)
KR (1) KR20120059526A (es)
CN (1) CN102596239A (es)
AU (1) AU2010280740A1 (es)
BR (1) BR112012002603A2 (es)
CA (1) CA2769610A1 (es)
EA (1) EA201290035A1 (es)
GB (1) GB0913681D0 (es)
MX (1) MX2012001527A (es)
SG (1) SG178169A1 (es)
WO (1) WO2011015591A1 (es)
ZA (1) ZA201200832B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
EP3199177A1 (en) * 2009-10-30 2017-08-02 GlaxoSmithKline Biologicals S.A. Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2013030378A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
CN102898511B (zh) * 2012-10-19 2014-05-07 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌重组基因工程疫苗候选抗原i12c制备中的纯化方法
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
CN103570835B (zh) * 2013-10-15 2015-07-29 黑龙江八一农垦大学 金黄色葡萄球菌itc融合蛋白及制备方法和应用
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3365357B1 (en) 2015-10-23 2024-02-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
JP2022526908A (ja) 2019-03-19 2022-05-27 ザ ブロード インスティテュート，インコーポレーテッド 編集ヌクレオチド配列を編集するための方法および組成物
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN112920259A (zh) * 2021-02-05 2021-06-08 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的IsdB抗原表位肽及其应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
AU3399197A (en) 1996-06-18 1998-01-07 Alza Corporation Device for enhancing transdermal agent delivery or sampling
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DE69720057T2 (de) 1996-12-20 2003-09-25 Alza Corp Vorrichtung und verfahren zur erhöhung des transdermalen wirkstoffeflusses
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
EP1121149A4 (en) 1998-08-31 2002-03-20 Inhibitex Inc IMMUNOTHERAPY METHOD FOR STAPHYLOCOCCAL INFECTIONS INCLUDING DONOR SELECTION AND DONOR STIMULATION
DE69940371D1 (de) 1998-09-14 2009-03-19 Nabi Biopharmaceuticals Rockvi Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CA2453937C (en) 2001-08-02 2013-05-14 University Of Sheffield Antigenic polypeptides
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
ATE419005T1 (de) 2001-12-11 2009-01-15 Merck & Co Inc Staphylococcus aureus exopolysaccharid und verfahren
PT2255826E (pt) 2002-08-02 2016-06-08 Glaxosmithkline Biologicals Sa Composições de vacina de neisseria compreendendo uma combinação de antigénios
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
RU2337108C2 (ru) 2003-07-24 2008-10-27 Мерк Энд Ко., Инк. Полипептиды для индукции защитного иммунного ответа против staphylococcus aureus
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ATE464066T1 (de) 2004-05-11 2010-04-15 Staat Der Nederlanden Vert Doo Neisseria meningitidis igtb los als adjuvans
DE102004047583A1 (de) * 2004-09-22 2006-04-06 Behr Gmbh & Co. Kg Wärmetauscheranordnung für den Frontbereich eines Kraftfahrzeugs
ES2472441T3 (es) 2004-09-22 2014-07-01 Glaxosmithkline Biologicals S.A. Composición inmunog�nica para uso en vacunación contra estafilococos
KR20070085457A (ko) 2004-10-25 2007-08-27 더 유니버시티 오브 웨스턴 온타리오 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CN101528202A (zh) * 2006-07-05 2009-09-09 特瓦制药工业有限公司 美金刚的药物组合物
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
KR20120059526A (ko) 2012-06-08
EA201290035A1 (ru) 2012-07-30
AU2010280740A1 (en) 2012-03-08
BR112012002603A2 (pt) 2016-11-22
SG178169A1 (en) 2012-03-29
CA2769610A1 (en) 2011-02-10
WO2011015591A1 (en) 2011-02-10
US20120141523A1 (en) 2012-06-07
ZA201200832B (en) 2014-07-30
EP2461824A1 (en) 2012-06-13
JP2013501027A (ja) 2013-01-10
GB0913681D0 (en) 2009-09-16
CN102596239A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
MX2012001527A (es) Composicion inmunogenica que comprende proteinas antigenicas de s. aureus.
MX2012000765A (es) Dominios variables sencillos de union de albumina anti-suero mejorados.
TN2015000247A1 (en) Bcma antigen binding proteins
NZ703581A (en) Anti-cd70 antibody drug conjugates
UA111818C2 (uk) Антитіло проти csf-1r
TN2010000213A1 (en) Wise binding antibodies and epitopes
TN2014000134A1 (en) Therapeutic peptides
PH12014501108A1 (en) Anti-il-36r antibodies
PH12014501924A1 (en) Xten conjugate compositions and methods of making same
MY161909A (en) Anti-her3 antibodies and uses thereof
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MX2019000046A (es) Anticuerpos anti-il-23.
SG159458A1 (en) Novel immunoglobulin-binding proteins with improved specificity
EA201490768A1 (ru) Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
MX2012013406A (es) Variantes de union mejoradas anti-albumina serica.
MX2015005756A (es) Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4.
MY180374A (en) An immunoglobulin fc conjugate which maintains binding affinity of immunoglobulin fc fragment to fcrn
MX2010003757A (es) Composiciones que comprenden multimeros optimizados de her1 y her3 y sus metodos de uso.
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
MX2013002055A (es) Variantes anti-enlace de albumina de suero mejodas.
WO2012122533A3 (en) Compositions and methods related to antibodies to staphylococcal proteins isda or isdb